Latest news for Alpha Tau Medical (NASDAQ:DRTSW) Stock

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.

Alpha Tau Medical Ltd

JP Morgan analyst Melissa Wedel maintains WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) with a Underweight and lowers the price target from $10 to $9.5.

News

Price Target

Analyst Ratings

JP Morgan Maintains Underweight on WhiteHorse Finance, Lowers Price Target to $9.5

Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) are duking it out for investor attention with <a href="https://www.benzinga.com/earnings">fourth-quarter earnings</a> being reported on Tuesday.
Both pharmaceutical heavyweights have very different technical setups, leaving investors to wonder which stock will have the upper hand.
Let's break down the charts and what the technical signals are saying about each company as they prepare to report.
<h1 class="wp-block-heading">Merck Stock's Mixed Signals: Bullish Short-Term, But Long-Term Resistance Looms</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM.png" alt="" class="wp-image-763045" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Merck stock has shown some solid short-term strength, with its stock price of $98.90 comfortably sitting above its eight-day and 20-day simple moving averages (SMAs) of $97.81 and $98.64, respectively. These short-term buying signals, along with a neutral Relative Strength Index (RSI) of 50.39, suggest a continuation of the current trend, barring any earnings surprises.
However, the story changes when looking at Merck stock&#8217;s long-term trend. Its 50-day SMA of $99.64 and 200-day SMA of $114.28 are higher than its stock price, indicating that the stock may face resistance moving forward. Merck&#8217;s Moving Average Convergence Divergence (MACD) of a negative 0.47 suggests bearish momentum in the near term, adding an element of risk.
On the flip side, analysts are bullish on Merck with a <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">consensus target of $124</a>, representing an implied upside of 20.25%. That positive outlook could be enough to offset the short-term technical pressure, making Merck stock a bit of a mixed bag heading into earnings.
Read Also: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
<h1 class="wp-block-heading">Pfizer Stock's Bearish Downtrend: Can It Overcome The Struggles?</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM.png" alt="" class="wp-image-763046" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
In stark contrast, Pfizer stock is looking much weaker technically. The stock has been firmly entrenched in a bearish trend, with its share price sitting below its five-, 20- and 50-day exponential moving averages (EMAs), signaling ongoing selling pressure. Pfizer stock at $26.30 has eight-day SMA at $26.51 and the 20-day SMA at $26.56, both signals pointing to potential further downside.
Pfizer stock's 50-day SMA of $26.15 provides some minor support, but overall, the chart points to more trouble ahead. The MACD indicator of 0.04 shows only a glimmer of bullish potential, while the RSI of 47.61 reinforces the neutral sentiment surrounding the stock. While there's a chance for some short-term recovery, Pfizer's overall trajectory looks weaker than Merck's.
Despite the challenges, Pfizer's analyst <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">consensus price target</a> is $36.74, offering an implied upside of 13.80%. However, with the Pfizer stock trading significantly below its 200-day SMA of $27.87, it's clear Pfizer has a tough road ahead.
<h1 class="wp-block-heading">Merck Vs. Pfizer: Who Will Win The Earnings Showdown?</h1>
When it comes to earnings, Merck's solid analyst outlook and bullish short-term signals seem to give it the edge over Pfizer, which is struggling with technical bearishness. 
While both stocks face risks, Merck's upside potential, supported by a 20% price target boost from analysts, makes it the more promising candidate for investors looking for stability and growth. 
Pfizer, on the other hand, remains a riskier play, though it does offer some upside potential if it can overcome its technical hurdles.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a></li>
</ul>
Photo: Merck: Zah108; Pfizer: Vadi Fuoco

Biotech

Health Care

Technicals

Previews

Trading Ideas

General

Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?

JP Morgan analyst Tami Zakaria maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Overweight and lowers the price target from $300 to $295.

JP Morgan Maintains Overweight on Illinois Tool Works, Lowers Price Target to $295

As of Feb. 3, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Ecopetrol SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>)</h3>
<ul>
<li>On Monday, Ecopetrol disclosed that Ecopetrol Permian LLC and Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) have planned to extend the development plan for Rodeo Midland Basin in the Permian Basin (Texas, USA). The agreement between Ecopetrol Permian and Occidental Petroleum, under the joint venture formed in July 2019, includes a drilling plan for 34 wells to be executed between April 2025 and June 2026, in addition to the ongoing wells planned for early 2025.. The company's stock surged around 16% over the past month and has a <a href="https://www.benzinga.com/quote/EC">52-week high of $12.90</a>.</li>
<li>RSI Value: 71.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>EC Price Action: Shares of Ecopetrol gained 3.1% to trade at $9.58 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Core Natural Resources Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNR#NYSE">CNR</a>)</h3>
<ul>
<li>On Jan. 31, Jefferies analyst Christopher LeFemina initiated coverage on Core Natural Resources with a Hold rating and announced a price target of $93. The company's stock gained around 825% over the past five years and <a href="https://www.benzinga.com/quote/CNR">has a 52-week high</a> of $134.14.</li>
<li>RSI Value: 70.6</li>
<li>CNR Price Action: Shares of Core Natural Resources fell 3.9% to trade at $86.92 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Short Ideas

Markets

Top 2 Energy Stocks That May Fall Off A Cliff In February

JP Morgan analyst Casey Woodring maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $280 to $265.

ICLR

JP Morgan Maintains Overweight on Icon, Lowers Price Target to $265

HCW Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration (FDA) for its Phase 1<a href="https://www.benzinga.com//node/43430431"> trial of HCW9302</a>.
The Details: The company&#8217;s HCW9302 is a potential treatment for moderate-to-severe alopecia areata, which is an autoimmune disease. Currently, there are no curative FDA-approved treatments for the disease.
The Phase 1 trial aims to establish a safe and effective dose of HCW9302. If successful, the company will proceed with Phase 2 studies to test the drug in other autoimmune diseases and inflammatory conditions, including dermatological disorders and diabetes.
Alopecia areata causes sudden hair loss and can have a significant negative impact on a patient&#8217;s quality of life and psychological health.
&#8220;The FDA&#8217;s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative immunotherapeutic treatment of autoimmune diseases. This trial is a milestone for our Company, and the beginning of clinical development of treatments for quality-of-life indications,&#8221; said Dr. Hing C. Wong, Founder and CEO of HCW.
HCW stock is trading on higher than normal session volume at 311.50 million shares. The company&#8217;s average session volume over the past 100 days is 9.61 million shares, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
See Also: <a href="https://www.benzinga.com/25/02/43443639/nike-to-rally-around-24-here-are-10-top-analyst-forecasts-for-monday">Nike To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday</a>
HWCB Price Action: At the time of writing HCW stock is trading 138.7% higher at 66 cents, per data from<a href="https://www.benzinga.com/pro/"> Benzinga Pro</a>.
Image: via Shutterstock

Movers

HCWB

What's Going On With HCW Biologics Stock Monday?

Fartcoin (CRYPTO: FARTCOIN) is recovering faster from a <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43433440/dont-buy-the-dip-on-bitcoin-ethereum-xrp-yet-standard-chartered-warns">temporary market downturn</a> than rivals Dogecoin and Shiba Inu, drawing renewed attention from traders on social media.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td> $0.7934</td>
<td>$793.4 million</td>
<td>+38%&nbsp;</td>
<td>-13.5%&nbsp;</td>
</tr>
<tr>
<td>Pudgy Penguins (CRYPTO: PENGU)</td>
<td> $0.01287</td>
<td>$809.2 million</td>
<td>+0.6%&nbsp;</td>
<td>-41.8%&nbsp;</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td> $0.8185</td>
<td>$814.07 million</td>
<td>-20.5%&nbsp;</td>
<td>-26.9%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Cold Blooded Shiller noted that Fartcoin has twice tested key resistance and is now breaking higher after a full wipeout of the past two months&#8217; upside.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Target region tapped twice. FARTCOIN beginning to move higher. A long way to go but all of the upside PA wiped out from the last 2 months into capitulation style conditions in the market. Seems good RR. <a href="https://t.co/QAePbRuuhu">https://t.co/QAePbRuuhu</a> <a href="https://t.co/crGlT6R1ID">pic.twitter.com/crGlT6R1ID</a>
&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1886438479082524909?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader Kaleo jumped in, revealing that he bought at the current level, calling it one of the strongest post-crash rebounders. He <a href="https://x.com/CryptoKaleo/status/1886251766414545040">believes</a> the coin's momentum will accelerate toward $1.
Kook Capital argues that Fartcoin is the only meme coin from this cycle with multi-cycle staying power. 
Unlike other tokens that fade after hype dies, the meme coin&#8217;s appeal <a href="https://x.com/KookCapitalLLC/status/1886444871923257775">extends</a> beyond crypto—second only to Bitcoin, according to the trader.
Statistics: AI analytics platform Nansen noted that the Fartcoin whales are <a href="https://x.com/nansen_ai/status/1886391716426789013">accumulating</a> and in the past 24 hours more than $6 million in FARTCOIN have been purchased.
Crypto trader ElonMoney revealed that over the past seven days mindshare levels have changed significantly <a href="https://x.com/0xelonmoney/status/1886446953375932548">reflecting</a> that while all tokens have lost attention, Fartcoin's mindshare has actually increased.
CryptoRank <a href="https://x.com/CryptoRank_io/status/1886434385479553133">noted</a> that Fartcoin futures volume on Binance touched $1.63 billion in the past 24 hours.
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/25/01/43376047/are-fartcoin-moodeng-tokens-securities-memecoin-creator-pumpfun-slapped-with-class-action-lawsuit">Are Fartcoin, MooDeng Tokens Securities? Solana-based Memecoin Creator Pump.fun Slapped With Class-Action Lawsuit</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$LINK

$WIF

Fartcoin Rebounds 38% In A Day, Outpaces Dogecoin, Shiba Inu

JP Morgan analyst Ken Goldman maintains Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) with a Neutral and lowers the price target from $8 to $6.

HAIN

JP Morgan Maintains Neutral on Hain Celestial Group, Lowers Price Target to $6

Shares of Homebuilders Fall After Trump Imposes Tariffs

Hartford Finl Servs Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) short percent of float has risen 3.38% since its last report. The company recently reported that it has 3.82 million shares sold short, which is 1.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hartford Finl Servs Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738608323_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hartford Finl Servs Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hartford Finl Servs Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hartford Finl Servs Gr's peer group average for short interest as a percentage of float is 2.01%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

How Is The Market Feeling About Hartford Finl Servs Gr?

Snap's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) short percent of float has fallen 12.13% since its last report. The company recently reported that it has 76.75 million shares sold short, which is 8.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Snap Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738608318_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Snap has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Snap's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Snap's peer group average for short interest as a percentage of float is 7.12%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SNAP

Peering Into Snap's Recent Short Interest

Shift4 Payments's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) short percent of float has risen 9.79% since its last report. The company recently reported that it has 7.69 million shares sold short, which is 11.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Shift4 Payments Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738608313_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Shift4 Payments has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Shift4 Payments's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Shift4 Payments's peer group average for short interest as a percentage of float is 4.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FOUR

Peering Into Shift4 Payments's Recent Short Interest

U.S. CBP: Chinese Imports Eligible For Temporary Duty Exemptions Will Be Subject To Additional 10% U.S. Tariff -Federal Register

JP Morgan analyst Andrea Teixeira maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $103 to $97.

JP Morgan Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $97

JP Morgan analyst Casey Woodring maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $215 to $175.

JP Morgan Maintains Neutral on Charles River, Lowers Price Target to $175

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Constellation Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)</h3>
<ul>
<li>On Monday, Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target to $200. The company' stock fell around 20% over the past month and has a <a href="https://www.benzinga.com/quote/STZ">52-week low of $166.02</a>.</li>
<li>RSI Value: 28.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>STZ Price Action: Shares of Constellation fell 2.1% to trade at $177.09 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">latest STZ news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9.png" alt="" class="wp-image-763223" style="width:531px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9-768x707.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">J &amp; J Snack Foods Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>J &amp; J Snack Foods will release its fiscal 2025 first quarter financial results, after the closing bell today. The company's stock fell around 13% over the past month and <a href="https://www.benzinga.com/quote/JJSF">has a 52-week low</a> of $132.88.</li>
<li>RSI Value: 23.4</li>
<li>JJSF Price Action: Shares of J &amp; J Snack Foods dipped 3.2% to trade at $132.88 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">JJSF stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10.png" alt="" class="wp-image-763224" style="width:515px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10-768x694.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">elf Beauty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>)</h3>
<ul>
<li>LiveWire Group will release its fourth quarter and year-end financial results before the opening bell on Wednesday, Feb. 5. The company's stock fell around 25% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ELF">low of $92.20</a>.</li>
<li>RSI Value: 26.4</li>
<li>ELF Price Action: Shares of elf Beauty fell 5.3% to trade at $94.57 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">ELF shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="890" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11.png" alt="" class="wp-image-763227" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11.png 890w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11-768x731.png 768w" sizes="(max-width: 890px) 100vw, 890px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Long Ideas

JJSF

Top 3 Risk Off Stocks That May Surge This Quarter

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading lower on Monday following President Donald Trump&#8217;s announcement that tariffs on all products from Canada, Mexico and China will take <a href="https://www.benzinga.com//node/43435750">effect on Tuesday</a>.
The Details: According to <a href="https://edition.cnn.com/2025/02/01/economy/trump-tariffs-mexico-canada-china-increased-costs/index.html">CNN</a>, Trump imposed a 25% tariff on all imported goods from Canada and Mexico, along with an additional 10% tariff on goods from China. Energy exports from Canada, however, will be subject to a reduced tariff of 10%.
Trump has since paused his tariffs on Mexico for a month after Mexican President Claudia Sheinbaum agreed to send troops to the border, per <a href="https://www.cnbc.com/2025/02/03/trump-tariffs-mexico-canada-china-sheinbaum-responds.html">CNBC</a>.
The tariffs are expected to impact the auto industry significantly. Last year, the U.S. imported roughly $87 billion in motor vehicles and $64 billion in vehicle parts from Mexico, excluding December. From Canada, the U.S. imported around $34 billion in motor vehicles between January and November.
The electric vehicle industry may be particularly affected, as companies could depend on imported components like batteries and semiconductors. These increased costs may ultimately be passed on to consumers.
Trump reportedly stated that while Americans might feel &#8220;some short-term pain&#8221; from the tariffs, in the long run, the U.S. has been &#8220;ripped off by virtually every country.&#8221;
In response, Canadian Prime Minister Justin Trudeau has retaliated by imposing tariffs on American products. Specifically, Trudeau announced a 25% tariff on around $105 billion worth of U.S. goods. 
What Else: Last week, Tesla announced <a href="https://www.benzinga.com//node/43321103">fiscal results</a> for the 2024 fiscal-year and fourth-quarter. For the fourth-quarter, Tesla reported adjusted earnings per share of 73 cents, missing analysts estimate of 76 cents. In addition, the company announced sales of $25.70 billion, missing analysts estimate of $27.26 billion.
Tesla also reported a 7% year-over-year decline in fourth-quarter production, while deliveries increased by 2% compared to the same period last year.
Related Link: <a href="https://www.benzinga.com/25/02/43440939/chipotle-mexican-grill-q4-earnings-preview-new-store-figures-comparable-sales-on-watch">Chipotle Mexican Grill Q4 Earnings Preview: New Store Figures, Comparable Sales On Watch</a>
TSLA Price Action: At the time of writing, Tesla stock is trading 6.00% lower at $380.19, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

TSLA

What's Going On With Tesla Stock Monday?

JP Morgan analyst Seth Seifman maintains Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) with a Underweight and lowers the price target from $142 to $140.

JP Morgan Maintains Underweight on Booz Allen Hamilton, Lowers Price Target to $140

JP Morgan analyst Jeffrey Zekauskas maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Overweight and raises the price target from $370 to $390.

JP Morgan Maintains Overweight on Sherwin-Williams, Raises Price Target to $390

JP Morgan analyst Melissa Wedel maintains Runway Gwth Fin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) with a Neutral and raises the price target from $10.5 to $11.

RWAY

JP Morgan Maintains Neutral on Runway Gwth Fin, Raises Price Target to $11

Press Releases

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Earnings

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Management

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

DRTS

DRTSW

Alpha Tau Medical

JERUSALEM, May 23, 2022 /PRNewswire/ -- Alpha Tau Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTS#NASDAQ">DRTS</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTSW#NASDAQ">DRTSW</a>),&nbsp;the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT&trade;,&nbsp;announced today that the first patients&nbsp;in its French multicenter trial for skin cancer were&nbsp;treated with Alpha DaRT, at the Leon Berard Center in Lyon, France by Dr. Pascal Pommier and his team. The Leon Berard Center specializes in radiotherapy for cancer and&nbsp;is affiliated with the National Federation of Cancer Centers in France - UNICANCER Group. Dr. Pommier is the Principal Investigator of the French multicenter study and has more than&nbsp;20 years of experience in radiation oncology and leading clinical trials.

Comments

Alpha Tau Medical

News

Latest news for Alpha Tau Medical (NASDAQ:DRTSW) Stock

Monday, May 23, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga